Abstracts tagged "SLE"

Abstract Number: 124 • 2016 ACR/ARHP Annual Meeting
Socioeconomic-Demographic, Disease Activity, Treatment and Immunologic Variables Affect B Cell Subtypes in Systemic Lupus Erythematosus
Arlene Bravo¹, Michelle T. Ngo², Michael De Vera³, Karina Marianne D. Torralba^2,4 and Abigail Benitez^2,4, ¹Internal Medicine, Loma Linda University, Loma Linda, CA, ²Rheumatology, Loma Linda University, Loma Linda, CA, ³Transplant Surgery, Loma Linda University, Loma Linda, CA, ⁴Transplantation Institute, Loma Linda University, Loma Linda, CA
Background/Purpose: B cell subset proportions within the B cell pool, also known as B cell signatures (BCS), reflect not only systemic lupus erythematosus (SLE) disease…
Abstract Number: 968 • 2016 ACR/ARHP Annual Meeting
Urinary Soluble CD163, an M2 Macrophage Marker, Reflects the Renal Disease Activity in Lupus Nephritis: A Cross Sectional and Longitudinal Assessment
Ranjan Gupta¹, Akhilesh Yadav² and Amita Aggarwal¹, ¹Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, ²Department of Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India
Background/Purpose: Alternatively activated (M2) macrophages are the major macrophage subtype infiltrating the glomeruli in lupus nephritis (LN). CD163 is a marker of M2 macrophages. In…
Abstract Number: 1388 • 2016 ACR/ARHP Annual Meeting
Distinct Clinical Correlates of Immune Thrombocytopenic Purpura at Diagnosis of Childhood-Onset and Adult SLE
Gladys Esteves¹, Natali W. Gormezano², Oriany Pereira¹, David Kern¹, Katia T. Kozu², Rosa M R Pereira³, Clovis A Silva⁴, Eloisa Bonfa⁵ and Nadia E Aikawa⁶, ¹University of São Paulo, São Paulo, Brazil, ²Pediatric Rheumatology Unit, University of São Paulo, São Paulo, Brazil, ³Rheumatology, University of São Paulo, São Paulo, Brazil, ⁴Pediatric Rheumatology Unit, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁵Rheumatology Divison, Hospital das Clinicas, Faculdade de Medicina, University of São Paulo, São Paulo, Brazil, ⁶Rheumatology Division, University of São Paulo, São Paulo, Brazil
Background/Purpose: Hematologic abnormalities are common manifestations in systemic lupus erythematosus (SLE) patients. Several studies have demonstrated a higher frequency of immune thrombocytopenic purpura (ITP) in…
Abstract Number: 1829 • 2016 ACR/ARHP Annual Meeting
Hyper-Responsiveness to TLR-4 Stimulation in SLE: Association with High Levels of Serum IFN-Alpha and a Distinct Inflammatory Cytokine Profile
Uma Thanarajasingam¹, Mark A. Jensen², Jessica M. Dorschner³, Danielle Vsetecka³, Shreyasee Amin⁴, Ashima Makol⁴, Floranne C. Ernste⁵, Thomas Osborn⁴, Vaidehi Chowdhary⁴ and Timothy B. Niewold⁶, ¹Division of Rheumatology, Mayo Clinic, Rochester, MN, ²Department of Immunology and Division of Rheumatology, Mayo Clinic, Rochester, MN, ³Division of Rheumatology and Department of Immunology, Mayo Clinic, Rochester, MN, ⁴Rheumatology, Mayo Clinic, Rochester, MN, ⁵Division of Rheumatology, Mayo Clinic Rochester, Rochester, MN, ⁶Rheumatology and Immunology, Mayo Clinic, Rochester, MN
Background/Purpose: IFN-alpha is a pathogenic factor in SLE. High serum interferon activity (IFN-high) marks a subgroup of SLE patients strongly associated with double-stranded DNA (dsDNA) antibodies.…
Abstract Number: 2830 • 2016 ACR/ARHP Annual Meeting
Non-Calcified Coronary Artery Plaque Associates with Adverse Lipoprotein Profiles in Systemic Lupus Erythematosus
Laura Durcan¹, Armin Zadeh², Margery Connelly³, James Otvos³, Laurence S Magder⁴ and Michelle Petri⁵, ¹University of Washington, Seattle, WA, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³LabCorp, Raleigh, NC, ⁴Epidemiology and Public Health, Division of Rheumatology, School of Medicine, Johns Hopkins University, Baltimore, MD, ⁵Rheumatology Division, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Systemic lupus erythematosus (SLE) associates with atherosclerotic cardiovascular (CV) disease and related mortality. This is contributed to, but cannot be fully explained, by traditional…
Abstract Number: 2989 • 2016 ACR/ARHP Annual Meeting
Risk of Cardiovascular Disease Events Among Patients with Systemic Lupus Erythematosus Compared to Those with Diabetes Mellitus in a Nationwide Medicaid Cohort
Medha Barbhaiya¹, Candace H. Feldman¹, Sarah K. Chen², Hongshu Guan³, Tzu-Chieh Lin¹, Michael A. Fischer⁴, Daniel H. Solomon⁵, Brendan M. Everett⁶ and Karen H. Costenbader¹, ¹Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ²Beth Israel Deaconess Medical Center, Boston, MA, ³Rheumatology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁴Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁵Division of Rheumatology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁶Division of Cardiovascular Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Cardiovascular disease (CVD) risk is elevated in SLE patients compared to non-SLE patients. However, how CVD rates differ in SLE patients compared with other…
Abstract Number: 176 • 2016 ACR/ARHP Annual Meeting
Endoplasmic Reticulum Stress Induces Lupus Kidney Disease By Facilitating Antigen Cross-Presentation Via the Increase of Endosomal Sec61
Ken Tsumiyama and Shunichi Shiozawa, Department of Medicine, Rheumatic Diseases Unit, Kyushu University Beppu Hospital, Beppu, Japan
Background/Purpose: Repeated immunization with exogenous antigen such as ovalbumin (OVA) induces SLE in mice otherwise not prone to spontaneous autoimmune diseases, in which autoantibody-inducing CD4…
Abstract Number: 990 • 2016 ACR/ARHP Annual Meeting
Autoimmunity to Multiple Antigens Is Expanded in at-Risk Family Members Beyond the Disease Specific Patterns of the SLE or RA Proband
Judith A. James¹, Krista M. Bean², Hua Chen², Kendra A. Young³, Elizabeth A. Bemis⁴, Jennifer Seifert⁵, Maria Sargent⁶, Kevin D. Deane⁷, Bill Robinson⁸, David A. Hafler⁹, Kevin O'Conner¹⁰, Jane H. Buckner¹¹, Joel M. Guthridge¹², Jill M. Norris¹³ and V. Michael Holers¹⁴, ¹Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Epidemiology, University of Colorado Denver, Aurora, CO, ⁴Epidemiology, Colorado School of Public Health, Aurora, CO, ⁵University of Colorado, Denver, CO, ⁶Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁷Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, ⁸Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, ⁹Neurology and Immunobiology, Yale School of Medicine, New Haven, CT, ¹⁰Yale University, New Haven, CT, ¹¹Benaroya Research Institute at Virginia Mason, Seattle, WA, ¹²Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹³University of Colorado Denver, Aurora, CO, ¹⁴Rheumatology Division, University of Colorado School of Medicine, Aurora, CO
Background/Purpose: Certain autoantibodies (aabs) are highly disease specific, can be detected prior to the onset of clinically apparent disease and oftentimes increase in number and…
Abstract Number: 1394 • 2016 ACR/ARHP Annual Meeting
A Pilot Study of Consensus Treatment Plans for Induction Therapy in Childhood Proliferative Lupus Nephritis
Jennifer C. Cooper¹, B. Anne Eberhard², Marilynn Punaro³, Stacy P. Ardoin⁴, Hermine I. Brunner⁵, Joyce Hsu⁶, Linda Wagner-Weiner⁷, Kelly Rouster-Stevens⁸, Laura E. Schanberg⁹, Marisa Klein-Gitelman¹⁰, Emily von Scheven¹¹ and CARRA Registry Investigators, ¹Pediatrics, Divison of Rheumatology, University of California, San Francisco, San Francisco, CA, ²Cohen Children's Medical Center of New York, New Hyde Park, NY, ³Texas Scottish Rite Hospital for Children, Dallas, TX, ⁴Pediatric & Adult Rheumatology, Ohio State University, Columbus, OH, ⁵Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁶Pediatric Rheumatology, Stanford University, Palo Alto, CA, ⁷Pediatric Rheumatology, University of Chicago Hospitals, Chicago, IL, ⁸Pediatric Rheumatology, Emory University School of Medicine, Atlanta, GA, ⁹Pediatrics, Duke Medical Center, Durham, NC, ¹⁰Division of Rheumatology, Department of Pediatrics, Ann & Robert H. Lurie Children’s Hospital of Chicago/Northwestern University Feinberg School of Medicine, Chicago, IL, ¹¹Division of Rheumatology, Department of Pediatrics, University of California, San Francisco, San Francisco, CA
Background/Purpose: Childhood-onset systemic lupus erythematous (cSLE) patients are at higher risk for renal disease than those with adult-onset disease. Mycophenolate mofetil (MMF) and intravenous…
Abstract Number: 1836 • 2016 ACR/ARHP Annual Meeting
SLE Bone Marrow Contains Factors That Promote Type I Interferon Activation
Nida Meednu¹, Anna Bird², Jennifer Barnard², Mariana Kaplan³ and Jennifer H. Anolik², ¹Medicine- Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY, ²University of Rochester Medical Center, Rochester, NY, ³NIAMS/NIH, Bethesda, MD
Background/Purpose: SLE is characterized by the inappropriate activation of type I Interferon (IFN) and increases in apoptosis and NETosis by neutrophils, which in combination with…
Abstract Number: 2832 • 2016 ACR/ARHP Annual Meeting
Novel Gene Variants Associated with Cardiovascular Disease in Systemic Lupus Erythematosus
Dag Leonard¹, Andrei Alexsson¹, Johanna Dahlqvist², Kimberly Taylor³, Johanna K Sandling⁴, Christine Bengtsson⁵, Elisabet Svenungsson⁶, Christopher Sjöwall⁷, Andreas Jönsen⁸, Iva Gunnarsson⁶, Anders A. Bengtsson⁸, Solbritt Rantapaa-Dahlqvist⁵, Maija-Leena Eloranta¹, Ann-Christine Syvänen⁴, Lindsey A. Criswell⁹ and Lars Rönnblom¹, ¹Uppsala University, Department of Medical Sciences, Rheumatology and Science for Life Laboratory, Uppsala, Sweden, ²Uppsala University, Department of Medical Biochemistry and Microbiology Science for Life Laboratory, Uppsala, Sweden, ³University of California, San Francisco, Rosalind Russell / Ephraim P. Engleman Rheumatology Research Center, San Francisco, CA, ⁴Uppsala University, Department of Medical Sciences, Molecular Medicine and Science for Life Laboratory, Uppsala, Sweden, ⁵Umeå University, Department of Public Health and Clinical Medicine/ Rheumatology, Umeå, Sweden, ⁶Karolinska Institutet, Department of Medicine, Unit of Rheumatology, Stockholm, Sweden, ⁷Linköping University, Department of Clinical and Experimental Medicine Rheumatology/AIR, Linköping, Sweden, ⁸Lund University, Department of Clinical Sciences, Rheumatology, Lund, Sweden, ⁹Medicine, University of California, San Francisco, Rosalind Russell / Ephraim P. Engleman Rheumatology Research Center, San Francisco, CA
Background/Purpose: Methods: An association between a locus located on chromosome 14 and stroke/TIA was shown in both the Swedish (OR 1.8, p=0.0002) and the US…
Abstract Number: 3101 • 2016 ACR/ARHP Annual Meeting
Lipoprotein Profile and Serum Glycoprotein Acetylation As Markers of Cardiovascular Risk in Systemic Lupus Erythematosus
Simantini Sakhardande¹, Monica Purmalek¹, Yenealem Temesgen-Oyelakin², Maureen Sampson³, Aditya Joshi⁴, Alice Fike⁵, Michael Davis⁶, Taufiq Salahuddin⁷, Balaji Natarajan⁷, Joseph Lerman⁷, Zerai G. Manna⁸, Amit Dey⁹, Marcus Chen⁷, Sarfaraz Hasni⁸, Nehal N. Mehta⁷, Alan Remaley⁷ and Mariana Kaplan¹⁰, ¹Systemic Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ²National Institute of Arthritis and Musculoskeletal and Skin Diseases,, National Institutes of Health, Bethesda, MD, ³Department of Laboratory Medicine, National Institutes of Health, Bethesda, MD, ⁴National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, ⁵National Institutes of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁶NIH, Bethesda, MD, ⁷NHLBI, National Institutes of Health, Bethesda, MD, ⁸National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁹National Institutes of Health, Bethesda, MD, ¹⁰NIAMS/NIH, Bethesda, MD
Background/Purpose: The risk of atherosclerotic cardiovascular disease (CVD) is significantly increased in systemic SLE compared to age and gender matched controls. The implementation of nuclear…
Abstract Number: 753 • 2016 ACR/ARHP Annual Meeting
Vitamin D Improves Systolic Blood Pressure in SLE
Michelle Petri¹, Erik Barr² and Laurence S Magder³, ¹Rheumatology Division, Johns Hopkins University School of Medicine, Baltimore, MD, ²Epidemiology, University of Maryland, Baltimore, MD, ³Epidemiology and Public Health, Division of Rheumatology, School of Medicine, Johns Hopkins University, Baltimore, MD
Background/Purpose: Vitamin D insufficiency/deficiency is common in SLE. Both a cohort study and a randomized clinical trial have proven that Vitamin D supplementation improves SLE…
Abstract Number: 999 • 2016 ACR/ARHP Annual Meeting
Utility of Neutrophil CD64 Expression & sTREM-1 in Distinguishing Bacterial Infection from Disease Flare in SLE and ANCA Associated Vasculitis
Sajal Ajmani, Harshit Singh, Saurabh Chaturvedi, Mohit kumar Rai and Vikas Agrawal, Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India
Background/Purpose: Fever is a common presenting manifestation of systemic lupus erythematosus (SLE) and ANCA associated vasculitis (AAV). Treating physician is challenged to differentiate between disease…
Abstract Number: 1749 • 2016 ACR/ARHP Annual Meeting
The Role of Mucosal-Associated Invariant T (MAIT) Cells in Lupus Dermatitis
Goh Murayama¹, Asako Chiba², Hirofumi Amano³, Ken Yamaji¹, Naoto Tamura¹ and Sachiko Miyake⁴, ¹Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan, ²Juntendo Univ Sch of Med, Juntendo University School of Medicine, Tokyo, Japan, ³Department of Rheumatology and Internal Medicine, Juntendo University School of Medicine, Tokyo, Japan, ⁴Immunology, Juntendo University School of Medicine, Tokyo, Japan
Background/Purpose: Mucosal-associated invariant T (MAIT) cells are innate T cells that are restricted by MHC-related molecule-1 (MR1) and express a semi-invariant TCRa chain: Va7.2-Ja33 in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].